This is a Phase IV randomized, multi-center, open label trial to compare the clinical safety and efficacy of linezolid to vancomycin in the treatment of complicated skin and soft tissue infections due to methicillin-resistant staphylococcus aureus in adult subjects hospitalized for at least one day.

Official Title

Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue Proven to be due to Methicillin-Resistant Staphylococcus Aureus

Conditions

Staphylococcal Skin InfectionsSoft Tissue Infections

Study Type

Interventional

Study Design

Treatment, Randomized, Open Label, Active Control, Single Group Assignment

Further Details

Study Start

August 2004

Eligibility & Criteria

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both – Hospitalized male/female subjects at least 18 years of age – Signs and symptoms consistent with infection – Infection suspected to be due to Methicillin Resistant Staphylococcus Aureus – Subjects excluded with necrotizing fasciitis, gas gangrene, osteomyelitis – Subjects excluded if treated with a previous antibiotic with known activity against Methicillin Resistant Staphylococcus Aureus for more than 24 hours

Total Enrolment

1200

Contact Details

1-734-622-7600 ClinicalTrials.gov@Pfizer.com

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.